Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

E-Scape Bio

  • Julie Anne Smith, E-Scape Bio

E-Scape Bio is a biopharmaceutical company developing novel small-molecule therapeutics for patients with inherited forms of neurodegenerative diseases. The company's drug development pipeline includes small molecules targeting known genetic drivers of CNS disorders including an S1P5 agonist for the treatment of CNS lysosomal storage disorders, a Parkinson's disease program targeting LRRK2, and an Alzheimer's disease program targeting ApoE4.

  • Date:Tuesday, February 12
  • Time:9:45 AM - 10:00 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:22778
  • Goal for Presentation:Company Update
  • Company Website:http://www.e-scapebio.com
  • Company HQ City:South San Francisco
  • Company HQ State:California
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:63 Million
  • CEO/Top Company Official:Julie Anne Smith
  • Year Founded:2015
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:ESB1609
  • Development Phase of Primary Product:Pre-Clinical
Speakers
Julie Anne Smith
E-Scape Bio
Back